Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Brentuximab Vedotin for Steroid Refractory GvHD

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Massachusetts General Hospital
Sponsor:
Collaborators:
Seattle Genetics, Inc.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01596218
First received: May 9, 2012
Last updated: January 28, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)